Chemical blockers used to displace thyronine analog from albumin in analog kits for assay of free thyroxin (FT4) or free triiodothyronine (FT3) may also displace thyroxin (T4) or triiodothyronine (T3) from thyroxin-binding globulin (TBG), resulting in an apparent TBG dependence of results of free hormone estimates. We used equilibrium dialysis and antibody binding to assess the displacement of thyronine analogs and thyronines from albumin and TBG by use of chemical blockers. We chose a combination of two chemical blockers, which eliminated thyronine analog-albumin binding but minimized thyronine displacement from TBG for use in FT4 and FT3 assays. These blocked-analog free-hormone assays yielded accurate clinical results in euthyroid patients, hypo-and hyperthyroid patients, and in pregnant women. FT4 results were not entirely normalized in all nonthyroidally ill patients, indicating that decreased analog-albumin binding is not the only factor resulting in low FT4 results. In current While not previously recognized for free triiodothyronine (FF3), displacement of triiodothyronine (T3) from endogenous binding proteins, especially TBG, would result in erroneous FF3 estimates when a patient's TBG concentration differed significantly from those in the assay calibrators. Because the binding affinity of T3 for TBG is significantly less than that of T4 for TBG, competitive binding blockers may displace T3 more easily than T4 from TBG
The altered alanine-sidechain thyronine analogs used in free thyroid hormone assays are bound by serum albumin (1) (2) (3) (4) . Consequently, inaccurate estimates of ligand concentration may result because of differences in analog-albumin binding in the calibrators and serum samples (4,5). Use of chemical blockers of labeled analog-albumin binding eliminated this problem (6, 7) . The estimates of free hormone produced by these chemically blocked assays appeared, however, to have an artifactual dependence upon serum thyroxin-binding globulin (TBG) concentration (8, 9). 3 We used equilibrium dialysis to evaluate the disassociation of thyroxin (T4) and an altered alanine-sidechain T4 analog from albumin and from TBG in the presence of chemical blockers of thyronine binding (10) . In this way, we demonstrated that the apparent TBG dependency of these assays was not the result of T4 analog binding to TBG but to the undesired displacement of T4 from TBG. The resulting competitive displacement of labeled analog from antibody produced an estimate of free thyroxin (FF4) that was artifactually low or high, depending on the quantity of T4 Received August 5, 1987 ; accepted October 6, 1987.
While not previously recognized for free triiodothyronine (FF3), displacement of triiodothyronine (T3) from endogenous binding proteins, especially TBG, would result in erroneous FF3 estimates when a patient's TBG concentration differed significantly from those in the assay calibrators. Because the binding affinity of T3 for TBG is significantly less than that of T4 for TBG, competitive binding blockers may displace T3 more easily than T4 from TBG
(11).
We have used equilibrium-dialysis systems and, in addition, the quantification of antibody-extracted thyronine and thyronine analog to identify concentrations of chemical blockers that minimize binding of T4 analog and T3 analog to albumin but that avoid substantial displacement of T4 or T3 from TBG. We found that assays created by using chemical blocker concentrations determined in this way, with use of tracers and antisera from DPC, produce FF4 and FF3 estimates in patients' samples that appear to be essentially uninfluenced by alterations in serum albumin concentrations while avoiding any clinically significant dependence on TBG concentrations.
Materials and Methods

Chemical Blockers
We studied the unbound T4 and T4 analog and T3 and T3 analog available for antibody binding in the presence of various concentrations of chemical blockers of albumin binding, using equilibrium dialysis and antibody (coatedtube) binding. Two chemical blockers were studied: sodium salicylate (A) and 2,4-dinitrophenol (B). Their concentrations were chosen based on our earlier studies of DPC's FF4 system (10), and were chosen to produce analog blocking effects intermediate We prepared three solutions of charcoal-stripped human serum albumin (obtained from DPC), 16, 33, and 57 g/L, containing 10, 15, and 19 g of T4 per liter, and three solutions of charcoal-stripped TBG (also obtained from DPC), 5.6, 21, and 35 g/L, which had been subjected to anilinonaphthalene sulfonic acid and then dialyzed to remove this acid. These TBG pools contained 13,46, and 87 pg of T4 per liter. We were unable to measure T3 in any of the pools (T3 <150 ngfL).
Equilibrium Dialysis
We measured T4 analog, T4, T3 analog, and T3 binding by albumin and TBG in buffers containing no chemical blockers, and in the 23 buffers containing various concentra-tions of blockers A, B, or both, using equilibrium dialysis as previously described (10). The dialyzed or "free" fraction of ligand was calculated.
The T3 analog and T3 dialyses differed from T4 analog and T4 only in that a final 11-fold dilution rather than 21-fold was used. We applied appropriate corrections in calculating the free fractions.
Immunoextraction
We measured the antibody binding of T4 analog, T4, T3 analog, and T3 and calculated the percentage bound from each albumin and TBG solution in buffer containing no chemical blockers and in each of the 23 buffers. This was done as previously described (10), except that for T3 analog and T3 a 100-4 sample volume and a 3-h incubation were used.
Radiotracers
We used high specific activity 'I-labeled T4 analog, irs1 labeled T4, 'I-labeled T3 analog, and 1I-labeled T3, freshly prepared by DPC. These tracers contained 1.0 g of human serum albumin per liter and were used within seven days of iodination. The analog tracers are altered alanineaidechain thyronine analogs, such as have been used in all of the DPC FF4 or FF3 analog assays (12). Buffer blanks were included in the dialysis and antibody-extraction studies to account for the albumin present in each tracer used.
Radioactivity was quantified in a 20-well gamma counter, with associated data reduction (DPC).
Assays and Patients
We made measurements in serum samples from 71 euthyreid female (12 receiving replacement thyroid hormone) and 49 euthyroid male patients (five receiving replacement thyroid hormone), from 81 pregnant women in the first trimester and 38 in the third trimester), from 27 hyperthyroid (11 with T3 toxicosis) and 27 hypothyroid (14 partly treated) patients, and from 23 seriously but nonthyroidally ill patients. TBG concentrations in the euthyroid group ranged from 5.9 to 52 mg/L. DPC created new FF4 and FF3 assays by diluting irs1 labeled T4 analog and IrsIlabeled T3 analog in buffer 21. The protocols followed were the same as for the DPC production FF4 and FF3 assays. We measured FF4 and FF3 in all samples, using these new (buffer 21) assays. We measured total T4 and T3 uptake (Nuclear Medical Laboratories, Irvine, TX) and T3 (MAGIC; Ciba Corning, Medfield, MA) in all samples.
We calculated free thyroxin indices (FF41) as T4 x T3 uptake x i0 and free triiodothyrornne indices (FF31) as T3 x T3 uptake for all patients. Our reference ranges for these assays are: T4, 45-115 pgfL; T3 uptake, 35-45%; T3, 0. Patients' results for all assays are shown in Table 1 . The correlation between FF4 and FF3 results and TBG are shown in Table 2 .
Results
Discussion
Chemical blockers used to prevent albumin binding of labeled analogs in analog FF4 and FF3 assays may displace endogenous thyronines from their binding proteins as well, resulting in erroneous estimates of free hormone (1, 10). The effect of thyronine displacement on such estimates depends upon the amount of thyronine displaced from proteins in the serum sample relative to that displaced from proteins in the assay calibrators.
If the patient's total bound hormone exceeds that in the assay calibrators, as when TBG is supranormal, the results will be falsely high. Conversely, if the patient's total bound hormone is lower than that in the assay calibrators, results will be falsely low. This effect may be contrasted with that produced when labeled analog is sequestered by albumin in an unblocked analog assay (1,2). When labeled analog sequestration is low in the patient's sample relative to the assay calibrators, as is the case in the third trimester of pregnancy, there is more labeled analog available for binding by the antibody in the patient's sample-assay tube than in the assay calibrators, and a ilsely low estimate of free hormone results.
We wondered whether blocker concentrations could be Little T4 or T3 was displaced from TBG by either blocker. Because the TBG we used contained T4, we could calculate the mass of T4 displaced and bound by antibody. T3 was present in the TBG solutions in concentrations not detected by our T3 assay (<about 150 ng/L), so the mass of T3 displaced was not quantifiable. Even though we demonstrated more dialyzable T4 and T3 from TBG in the presence of blocker A than blocker B, this difference was barely discernible in the antibody-bound fractions of T4 and T3. Increasing concentrations of blockers A and B in mixtures had no effect on the amount (i.e., the mass) of T4 or T3 bound by antibody.
The thyronine analogs were not bound by TBG. Smaller proportions of dialyzable T4 analog in the presence of buffer B reflects binding of T4 by albumin present in the tracer. The decrease in carrier-free T4-analog-antibody binding as TBG increases is ascribable to competitive displacement of analog by the T4 that was present in the TBG solutions.
We saw little effect on the proportion of T3 dialyzed away from TI3G that could be attributed to albumin in the tracer. Because the TBG solutions were more nearly T3-free, differences in antibody binding of T3 analog due to displacement by T3 are not as marked as were seen for T4. Blocker A displaced more T4 from albumin than did blocker B, in the concentrations we used, but the two blockers were equally effective in displacing T3 from albumin. As was seen for T4, blocker A much more effectively displaced T3 analog from albumin than did blocker B.
The mixtures of blocker A and B did not displace more T4 or T3 from albumin than either did alone. Mixtures of blockers A and B did, however, more effectively displace T4 Amersham's Amerlex FF4 assay and their more recently 0. 39 introduced Magnetic FF4 and Magnetic FF3 assays. We used the old DPC FF4 and FF3 assays as well. These assays were formulated with old DPC buffer 5, which contains a higher concentration of blockers than are present in buffer 21 (10). We do not know whether the Amerlex assays contained blocking agents. Apparently, the Amerlex M assays do (3, 13). The Amerlex assays are no longer available from Amersham in the United States, having been replaced with Amerlex M assays.
FF4 results we obtained with the two Amersham assays and the DPC buffer-21 assay were similar in euthyroid patients. We included patients with low or above-normal TBG concentrations. All results were within the euthyroid range as estimated by these three FF4 assays. As has been reported by others (8,9), FF4 results obtained using the old buffer-5 DPC assay were increased in some samples with high TBG concentration and low in samples with low TBG concentration. There was no correlation between results for FF4 with the Amersham Amerlex kit and TBG; the correlation with the old DPC kit was great enough to result in clinical errors. FF4 estimates produced with the Amersham Magnetic assay and the DPC buffer-21 assay, in both of which chemical blockers of analog-albumin binding are used, correlate weakly with TBG concentrations.
All four FF4 assays produced similar results in patients with thyroidal dysfunction. We studied samples obtained from patients with partly treated or mild hypo-or hyperthyroidism. Partly treated hypothyroid patients, or patients with mild untreated hypothyroidism had a normal or lownormal value for FF41 and mildly increased thyrotropin. FF4 results in these patients were in the low-normal range. FF4 results were within the normal reference interval in most patients with T3 toxicosis and were increased in patients with hyperthyroidism who also had an increased FF41. There was no difference in the diagnostic accuracy of results obtained with the four assays for patients with overt hypo-or hyperthyroidism.
We T3-analog-albumin association than they demonstrated for their T4 analog. In both DPC assays, binding of T3 antibody by albumin is chemically blocked. In the old DPC FF3 assay, the higher concentration of blocking chemicals would be expected to displace T3 from TBG-present in these patients in concentrations lower than in the assay calibrators-and therefore contribute to artifactually low FF3 estimates. In the buffer-21 assay, however, displacement of T3 from TBG was slight. We observed results with the new buffer-21 FF3 assay that are, if anything, lower than those obtained with the old DPC assay. We suggest that although decreased albumin sequestration of the T3 analog tracer may artifactually lower FF3 results in non-thyroidal illness, these analog methods, like direct (26) and indirect (27) equilibrium dialysis and ultraifitration (25,28), probably reflect a true reduction in FF3.
In pregnancy, FF3 concentrations reportedly are unchanged from normal as measured by indirect equilibrium dialysis (22) , decline when direct RJ.A of dialysate is used (21) , and increase (25) or decrease (28) when estimated by ultrafiltration.
Lower FF3 concentrations have been reported with the old Amerlex assay, presumed to be due to decreased albumin sequestration of the T3 analog tracer (19). We observed lower Amerlex M results for FF3 in thirdtrimester relative to first-trimester samples, but these results were not significantly different from results obtained in non-pregnant euthyroid subjects. We measured no difference between results for samples collected during the first and third trimesters with either DPC assay. The effect of displacement of T3 from TBG probably is responsible for the higher FF3 results measured in pregnancy with the old DPC assay as compared with results obtained with the buffer-21 assay.
We have demonstrated that effects due to chemical blockers that competitively displace thyronines from endogenous binding proteins can be assessed by equilibrium dialysis and antibody binding. Our studies suggest that blocked-analog methods for FF4 and FF3 assay based on the DPC design have been optimized by a suitable choice of blocking-agent concentrations, to minimize susceptibility to albumin-related artifacts, while still avoiding any clinically significant TBG dependency.
